Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Feb;23(2):69-77.
doi: 10.1097/FPC.0b013e32835ca260.

Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment

Affiliations
Randomized Controlled Trial

Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment

Shaunna L Clark et al. Pharmacogenet Genomics. 2013 Feb.

Abstract

Objective: To examine the unique and congruent findings between multiple raters in a genome-wide association study (GWAS) in the context of understanding individual differences in treatment response during antipsychotic therapy for schizophrenia.

Materials and methods: We performed GWAS to search for genetic variation affecting treatment response. The analysis sample included 738 patients with schizophrenia, successfully genotyped for ∼492k single nucleotide polymorphisms (SNPs) from the Clinical Antipsychotic Trial of Intervention Effectiveness. Outcomes included both clinician and patient report of illness severity on global impression scales, the clinical global impression severity scale and patient global impression, respectively. Our criterion for genome-wide significance was a prespecified threshold ensuring that, on average, only 10% of the significant findings are false discoveries.

Results: Thirteen SNPs reached genome-wide significance. The top findings indicated three SNPs in PDE4D, 5q12.1 (P=4.2×10, 1.6×10, 1.8×10), mediating the effects of quetiapine on patient-reported severity and an additional three SNPs in TJP1, 15q13.1 (P=2.25×10, 4.86×10, 4.91×10), mediating the effects of risperidone on patient-reported severity. For clinician-reported severity, two SNPs in PPA2, 4q24 (P=3.68×10, 5.05×10), were found to reach genome-wide significance.

Conclusion: We found evidence of both a novel and a consistent association when examining the results from the patient and clinician ratings, suggesting that different raters may capture unique facets of schizophrenia. Although our findings require replication and functional validation, this study shows the potential of GWAS to discover genes that potentially mediate treatment response of antipsychotic medication.

PubMed Disclaimer

Figures

Figure 1
Figure 1
QQ Plots of Genome-Wide Significant Associations with Clinician (CGI-S) and Patient (PGI) Rated Global Impression Severity

References

    1. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–45. - PubMed
    1. Guy W. DHEW Publ No ADM 76-338. National Institute of Mental Health; Rockville, MD: 1976. Clinical Global Impressions ECDEU Assesment Manual fo Psychopharmacology, Revised; pp. 218–22.
    1. Bowie CR, Twamley EW, Anderson H, Halpern B, Patterson TL, Harvey PD. Self-assessment of functional status in schizophrenia. Journal of Psychiatric Research. 2007;41(12):1012–8. - PMC - PubMed
    1. Murray EJ. Measurement issues in the evaluation of psychopharmacological therapy. In: Fisher S, Greenberg RP, editors. The limits of biological treatments for psychological distress: Comparisons with psychotherapy and placebo. Hillsdale, NJ, England: Lawrence Erlbaum Associates, Inc; 1989. pp. 39–67.
    1. Lindstrom E, Jedenius E, Levander S. A symptom Self-rating Scale for Schizophrenia (4S): Psychometric properties, reliability and validity. Nordic Journal of Psychiatry. 2009;63(5):368–U4. - PubMed

Publication types